Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial

  • STATUS
    Recruiting
  • End date
    Dec 22, 2023
  • participants needed
    570
  • sponsor
    Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Updated on 26 February 2022
platelet count
measurable disease
growth factor
neutrophil count
EGFR
cetuximab
adenocarcinoma
adenocarcinoma of colon
modified folfox6

Summary

The study is an double blind, randomized, multicenter phase 3 trial. The efficacy analyses are based on 570 Chinese patients with RAS wt mCRC treated with mFOLFOX-6 cetuximab. Study treatment continues until disease progression or unacceptable toxicity (ie, not for a fixed number of courses). The primary endpoint of the study is progression-free survival (PFS) time according to RECIST 1.0; key secondary endpoints include overall survival (OS) time, overall response rate (ORR), and safety/tolerability.

Details
Condition Metastatic Colorectal Cancer
Treatment Placebo, KL-140
Clinical Study IdentifierNCT03426371
SponsorSichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Last Modified on26 February 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Signed written informed consent
Male or female subjects 18-75 years of age
Medically accepted effective contraception if procreative potential exists
Diagnosis of histologically confirmed adenocarcinoma of the colon or rectum
RAS wild-type and BRAF-V600E wild-type status in tumor tissue
At least one measurable lesion by computer tomography (CT) or magnetic resonance imaging (MRI) according to RECIST
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at trial entry
Life expectancy of at least 12 weeks
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at trial entry
White blood cell count >= 3 10x9/L with neutrophils >= 1.5 10x9/L, platelet count >=75 10x9/L and hemoglobin >= 8 g/dL Total bilirubin <= 1.5 upper limit of reference range Aspartate transaminase (AST) and alanine transaminase (ALT) <= 2.5 upper limit of reference range or <= 5 upper reference range in subjects with liver metastasisSerum creatinine <= 1.5 upper limit of reference range

Exclusion Criteria

Known hypersensitivity or allergic reactions against any of the components of the trial treatments
Radiotherapy or surgery (excluding prior diagnostic biopsy) in the 28 days before trial treatment
Known brain metastasis and/or leptomeningeal disease. Subjects with neurological symptoms should undergo a CT scan/MRI of the brain to exclude brain metastasis
Acute or sub-acute intestinal occlusion or history of inflammatory bowel diseaseexcept the patient with fistulation or stenting
Active clinically serious infections (> grade 2 National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0), including active tuberculosis
Uncontrolled diabetes mellitus, pulmonary fibrosis, acute pulmonary disorder, interstitial pneumonia, or liver failure
Clinically significant cardiovascular disease, e.g. cardiac failure of New York Heart Association classes III-IV, uncontrolled coronary artery disease, cardiomyopathy, uncontrolled arrhythmia, uncontrolled hypertension, or history of myocardial infarction in the last 5 years, or left ventricular ejection fraction below the institutional range of normal on a baseline multiple gated acquisition scan or echocardiogram
Renal replacement therapy
Peripheral neuropathy > grade 1
History of organ allograft, autologous stem cell transplantation, or allogeneic stem cell transplantation
Previous malignancy other than CRC in the last 5 years except basal cell cancer of the skin or preinvasive cancer of the cervix
Known and declared history of human immunodeficiency virus (HIV) infection or chronic hepatitis B or C
Known severe coagulation disorders
Previous chemotherapy for CRC except adjuvant treatment if terminated > 12 months (oxaliplatin-based chemotherapy) or > 6 months (non-oxaliplatin-based chemotherapy) before the start of treatment in this trial
Previous treatment with anti-EGFR monoclonal antibody therapy
Other non-permitted concomitant anticancer therapies, chronic systemic immune therapy or hormone therapy
Granulocyte colony stimulating factor (G-CSF) or granulocyte macrophage colony stimulating factor (GM-CSF) within 3 weeks of trial entryblood transfusionor blood components transfusion
Pregnancy (absence to be confirmed by serum -human chorionic gonadotropin test) or breastfeeding
Ongoing alcohol or drug abuse
Known neurological or psychiatric diseases
Participation in another clinical trial within the past 4 weeks
Legal incapacity or limited legal capacity
Other significant disease that in the investigator's opinion should exclude the subject from the trial
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note